Innovation Hub

NorthX Biologics has been recognized by the Swedish Government to be an international Innovation hub for Advance Biologics and Advanced Therapy Medicinal Products (ATMPs). Our goal is to accelerate client projects and move them forward into clinical development through open collaboration in process and analytical development, connections with financiers (public or private) and further production for clinical or commercial applications. In the innovation hub early projects have access to modern infrastructure with competent staff and state of the art technology that allows a faster route to concept testing.

The Innovation Hub serves an important role in competence and capacity development of seamless transfer of projects between different clinical stages and quality levels.

NorthX is Beyond CDMO

Here at NorthX Biologics we talk about being more then a CMDO.  We want to go beyond the normal service company and do more for our clients.  This is why at NorthX we consider ourselves to be Beyond CDMO and a true Innovation hub to help support and grow with our clients.

Our Innovation hub is designed for just this…to grow with our clients and help them progress forward.  Sometimes that progression is in the form of service, or network or connections that we can help make within our extensive Life Science Ecosystem.  So, do you want to go Beyond CDMO and grow with us?

Applications of the Innovation Hub

Our services can be applied to many different areas and can begin with Process and Analytical Development and move into the following areas:

We can support various projects within Cell and Gene therapy via many of our offered services

  • Plasmid DNA-At NorthX Biologics Innovation Hub, we leverage the power of plasmid DNA to drive advancements across various fields. Our expertise in plasmid DNA technology enables us to develop innovative solutions for gene therapy and vaccine production. By utilizing cutting-edge techniques, we ensure high-quality plasmid DNA production that meets the rigorous demands of these applications. Whether for therapeutic gene delivery, or the creation of next-generation vaccines, NorthX Biologics is at the forefront of plasmid DNA innovation, providing robust and reliable solutions to advance healthcare.
  • Viral Vector Manufacturing- At NorthX Biologics Innovation Hub, we harness the potential of viral vectors to revolutionize various therapeutic applications. Our state-of-the-art expertise in viral vector technology enables us to develop and produce high-quality vectors for gene therapy, vaccine development, and advanced therapeutic research. By employing cutting-edge techniques, we ensure efficient and safe viral vector production tailored to meet the specific needs of each application. From delivering genetic material for treating diseases to creating innovative vaccines, NorthX Biologics is at the forefront of viral vector innovation, driving breakthroughs that enhance healthcare outcomes.
  • Aseptic Fill/Finish- Our state-of-the-art facility is equipped with Proven Isolator Technology, ensuring aseptic filling of vials in a C-graded cleanroom environment. We prioritize maintaining the highest levels of cleanliness and sterility throughout the production process to safeguard the integrity of your products.

At NorthX Biologics Innovation Hub, we are dedicated to revolutionizing vaccine development through our comprehensive suite of viral and non-viral delivery services. Our expertise spans both domains, providing innovative solutions to meet the growing demands of therapeutic and preventive vaccines.

Key Applications of Our Viral and Non-Viral Services in Vaccine Development:

Viral Vaccines:

  • Adenovirus Vectors: We specialize in the development and production of adenoviral vectors that serve as powerful platforms for vaccine delivery, stimulating robust immune responses against infectious diseases.
  • AAV and Lentiviral Vectors: Utilizing AAV and lentiviral vectors, we create vaccines that provide long-lasting immunity and are particularly suited for gene-based immunization strategies.
  • Oncolytic Viruses: Our expertise includes the use of oncolytic viruses to develop cancer vaccines, harnessing the ability of these viruses to selectively target and destroy tumor cells while eliciting an immune response.

Non-Viral Vaccines:

  • Virus-Like Particles (VLPs): Leveraging the structural properties of VLPs, we develop next-generation vaccines that mimic natural viral infections without containing genetic material, ensuring safety and efficacy.
  • Liposome-Based Vaccines: Our liposome formulation techniques enable the encapsulation of antigens, enhancing their stability and delivery, and providing a strong immune response.
  • Exosome-Based Vaccines: Utilizing exosomes, we create innovative vaccines that facilitate efficient antigen presentation and potent immune activation, suitable for a variety of infectious and non-infectious diseases.

Combined Approaches:

  • Hybrid Vaccines: Combining the strengths of viral and non-viral platforms, we develop hybrid vaccines that offer enhanced immunogenicity and safety, addressing the limitations of single-platform approaches.

Therapeutic Vaccines:

  • Cancer Vaccines: We develop both viral and non-viral therapeutic vaccines aimed at treating various types of cancer by inducing targeted immune responses against tumor-specific antigens.
  • Chronic Disease Vaccines: Our technologies support the creation of vaccines for chronic diseases, including autoimmune disorders and allergies, by modulating the immune system for long-term protection.

Preventive Vaccines:

  • Infectious Disease Vaccines: Our portfolio includes vaccines for preventing infectious diseases such as influenza, HIV, and emerging pathogens, using both viral and non-viral delivery systems to ensure broad protection and rapid response capabilities.
  • Pandemic Preparedness: We are committed to developing vaccines that can be rapidly deployed in response to pandemics, leveraging our advanced platforms to deliver scalable and effective solutions.

Learn more about our Viral and Non-Viral services here.

At NorthX Bio, we’re proud to offer a wide spectrum of protein production services, specializing in recombinant proteins. Our experienced team of scientists can take your gene sequence through gene cloning, plasmid construction, and expression-ready constructs, to final protein purification. We work with a range of expression systems and cell types – from E. coli to mammalian- ensuring optimal protein expression level for your target protein.

Applications of our Recombinant Protein services include:

  • Monoclonal Antibodies (mAbs)
  • Hormones
  • Cytokines
  • Enzymes
  • Fusion Proteins
  • Vaccines
  • Blood Factors
  • Growth Factors
  • Therapeutic Enzyme Inhibitors
  • Receptor Antagonists

”At the NorthX Innovation Hub, innovations in advanced biologics can be transformed into products and new treatments for patients, unlocking the full value of investments in R&D.”

Thomas Eldered- Chairman of the Board, NorthX Biologics

Leveraging our expertise and infrastructure, we accelerate your journey to clinical success and collaborate closely to overcome obstacles.

Let’s journey together

NorthX Biologics is dedicated to the journey of complex biologics. Let us know how we can help move your product forward.